Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Preferred Shares (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 3 years of Preferred Shares data on record, last reported at $1.0 in Q2 2025.

  • For Q2 2025, Preferred Shares fell 50.0% year-over-year to $1.0; the TTM value through Jun 2025 reached $1.0, down 50.0%, while the annual FY2024 figure was $2.0, N/A changed from the prior year.
  • Preferred Shares reached $1.0 in Q2 2025 per COEP's latest filing, roughly flat from $1.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $2.0 in Q2 2024 and bottomed at $1.0 in Q4 2021.
  • Average Preferred Shares over 3 years is $1.5, with a median of $1.5 recorded in 2021.
  • The widest YoY moves for Preferred Shares: up 50.0% in 2025, down 50.0% in 2025.
  • A 3-year view of Preferred Shares shows it stood at $1.0 in 2021, then soared by 100.0% to $2.0 in 2024, then tumbled by 50.0% to $1.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Shares were $1.0 in Q2 2025, $1.0 in Q1 2025, and $2.0 in Q4 2024.